0001193125-25-270081
SEC filingMD&A section not provided in document content; no financial data available.
The provided document content does not include the Management's Discussion and Analysis (MD&A) section. The text begins with Item 2 (Unregistered Sales of Equity Securities) and covers other items such as exhibits and certifications, but no discussion of financial condition, results of operations, or forward-looking information is present. Therefore, no analysis can be performed.
Total assets were $2.47B as of September 30, 2025, up from $2.39B at December 31, 2024. Cash and cash equivalents of $376.6M plus short-term investments of $9.8M provided $386.4M in liquidity. The $225.0M undrawn U.S. revolving credit facility adds further flexibility. Working capital improved to $889.7M from $848.6M. Total debt stood at $57.9M, split between $33.2M of short-term lines of credit and $24.9M of long-term debt (net of current portion $20.1M). Shareholders' equity rose to $1.89B from $1.80B, primarily driven by retained earnings. Noncontrolling interest declined to $58.3M from $73.6M, reflecting net changes in minority stakes.
Non-cancelable purchase commitments totaled $100.6M at quarter-end: $38.1M for capital expenditures (primarily manufacturing equipment) and $62.5M for wafer purchases, with wafer deliveries scheduled through 2031. Additionally, the Company has a defined benefit plan underfunded liability of $3.4M (UK plan), with required annual contributions of approximately $2.6M through 2028 and a final $2.0M payment in 2029.
During the nine months ended September 30, 2025, the Company repurchased $10.0M of common stock (211,000 shares). No dividends were paid. Capital expenditures totaled $52.7M (4.8% of net sales). Net debt was essentially flat: $6.5M in long-term debt proceeds and $4.1M in repayments, with short-term credit advances of $34.0M and repayments of $34.9M. Uses of cash included $49.3M for equity securities (Atlas investment increased by $17.3M, ATX joint venture $30.0M, minority interest acquisition $4.1M) and $10.0M in buybacks.
The Company operates as a single reporting segment (standard semiconductor products). The Notes provide geographic disaggregation based on the location of the subsidiary producing the sale. For Q3 2025: Asia net sales $240.8M (61.4% of total), Americas $127.4M (32.5%), Europe $24.0M (6.1%). By shipment destination, Asia accounted for $307.9M (78.5%), Europe $46.2M (11.8%), Americas $38.1M (9.7%). By sales type, distributor sales were $260.1M (66.3%) and direct sales $132.1M (33.7%). Customer concentration: two customers represented 13.2% and 11.4% of net sales in Q3 2025.
Operating cash flow (CFO) of $177.4M far exceeded net income of $56.9M, indicating strong cash generation relative to earnings. The primary drivers were non-cash charges (depreciation $91.0M, amortization $17.5M, share-based compensation $19.0M) and a significant working capital release: accounts receivable decreased $27.8M, inventory declined $12.6M, and accounts payable increased $10.0M. This contrasts with the prior year period where inventory built by $90.2M, suppressing CFO.
Capital expenditures of $52.7M were nearly flat year-over-year ($53.3M), representing a capex intensity of ~93% of net income but only 30% of CFO. The company continues to invest in property, plant, and equipment at a moderate pace.
Free cash flow (CFO minus capex) was $124.7M, providing ample coverage for the $10.0M in share repurchases. No dividends were paid. The company also generated $15.9M from the sale of a subsidiary and $5.7M from asset sales, partially offsetting investing outflows.